Deuterium-Labeled M1 Allosteric Modulators for Selective Cognitive Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a scarcity of potent and selective positive allosteric modulators of the M1 muscarinic acetylcholine receptor that are effective in treating neurological and psychiatric disorders associated with cholinergic activity, due to the high conservation of orthosteric binding sites, leading to adverse effects similar to acetylcholinesterase inhibitors.
Innovation Solution
Development of compounds with specific structures, such as those represented by formulas (I) and (II), which act as positive allosteric modulators of the M1 muscarinic acetylcholine receptor, exhibiting high affinity and selectivity, thereby modulating M1 receptor activity with minimal agonist activity to avoid cholinergic adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If selective M1 agonists are developed to enhance cognition in disorders such as AD and schizophrenia, then receptor activation and therapeutic efficacy are improved, but adverse effects similar to AChE inhibitors occur due to activation of peripheral mAChRs
Solution Approach 1:
The patent employs positive allosteric modulators as intermediary compounds that indirectly enhance M1 receptor activation by potentiating the binding and efficacy of endogenous acetylcholine, rather than directly activating the orthosteric binding site. This indirect mechanism allows for selective M1 receptor modulation while avoiding activation of peripheral mAChRs, thereby reducing adverse effects while maintaining therapeutic efficacy in cognitive disorders.
2Reliability
If orthosteric agonists are used to activate M1 receptors, then cognitive function is enhanced, but selectivity is reduced due to high conservation of the orthosteric ACh binding site
Solution Approach 1:
The patent transitions from orthosteric binding (one dimension) to allosteric modulation (another dimension). By targeting the allosteric site distinct from the highly conserved orthosteric ACh binding site, the invention achieves selective M1 receptor modulation. This dimensional shift allows compounds to differentiate between M1 and other mAChR subtypes based on unique allosteric site characteristics, thereby improving selectivity while maintaining cognitive enhancement effects.
3Reliability
If AChE inhibitors are used for palliative treatment of cognitive deficits, then cholinergic activity is increased, but disease modification is not achieved and adverse effects occur
Solution Approach 1:
The patent replaces AChE inhibitors with positive allosteric modulators as intermediary compounds. Instead of inhibiting acetylcholine breakdown (which increases overall cholinergic activity non-selectively), the allosteric modulators selectively enhance M1 receptor response to endogenous acetylcholine. This provides cognitive symptom relief through selective M1 potentiation while avoiding the broad cholinergic activation that causes adverse effects with AChE inhibitors.
Data Source
AI summary
Described are deuterium-labeled 6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one and isoindolin-1-one positive allosteric modulators of muscarinic acetylcholine receptor M1(mAChR M1), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric disorders, or a combination thereof.